Announcement PDF ANNUAL REPORT 30 JUNE 2018 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 Table of Contents Corporate Directory........................................................................................................................................................ 1 Directors' Report ............................................................................................................................................................ 2 Remuneration Report (Audited) ................................................................................................................................... 11 Auditor’s Independence Declaration ............................................................................................................................ 19 Consolidated Statement of Profit or Loss and Other Comprehensive Income ............................................................. 20 Consolidated Statement of Financial Position .............................................................................................................. 21 Consolidated Statement of Changes In Equity............................................................................................................. 22 Consolidated Statement of Cash Flows ....................................................................................................................... 23 Notes to the Financial Statements ............................................................................................................................... 24 Directors' Declaration ................................................................................................................................................... 46 Independent Auditors Report ....................................................................................................................................... 47 Corporate Governance Statement ............................................................................................................................... 52 ASX Additional Information .......................................................................................................................................... 58 Corporate Directory Directors Peter Molloy – Managing Director William Garner – Non Executive Chairman Chris Ntoumenopoulos – Non Executive Director John Cullity – Non Executive Director Company Secretary Peter Webse Registered office Level 2, 710 Collins Street Docklands VIC 3008 Ph: +3 9097 1656 Website: www.raceoncology.com Auditor Bentleys Audit & Corporate (WA) Pty Ltd 216 St Georges Terrace PERTH WA 6000 Share Registry Automic Registry Services Level 2 267 St Georges Terrace Perth WA 6000 Ph: + 8 9324 2099 Securities Exchange Listing Australian Securities Exchange Limited Level 40, Central Park 152-158 St Georges Terrace Perth, WA, 6000 ASX Code – RAC 1 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT Your Directors present their report, together with the financial statements of Race Oncology Limited (“the Company” or “RAC”) for the financial year ended 30 June 2018. Information on Directors Directors have been in office since the start of the financial year to the date of this report unless otherwise stated. Peter Molloy — Managing Director (appointed 1 July 2016) Qualifications — Experience — Bachelor of Science (Microbiology and Biochemistry), University of Melbourne Master of Business Administration, University of Adelaide Mr. Molloy worked in pharmaceutical industry for 18 years. At the Australian pharmaceutical company, Faulding, he managed several Faulding subsidiaries, before joining Pharmacia (now Pfizer) as Managing Director of its Australia and NZ operations and later as Vice President of Strategic Marketing for Asia-Pacific and Latin America. Subsequently, he served as CEO of three biotechnology companies – Biota Holdings Ltd, SLIL Biomedical Corp and Florigene Ltd – where he managed numerous R&D programs, raised substantial equity funding and executed four pharmaceutical partnerships. During his tenure as CEO of the ASX-listed company, Biota Holdings Ltd, the company’s market value grew from approximately $30m to nearly $300m in three and a half years. Previously, as CEO of the US company, SLIL Biomedical Corp, he managed R&D and licensing for the company’s oncology drug development program. Between 2008 and 2014, he was a non-executive director of immune-oncology company, Viralytics (ASX:VLA). During his career, he has managed seven biotechnology or pharmaceutical businesses, launched 23 pharmaceutical products, and executed 40 international licensing or distribution deals. Interest in Shares and Options — 4,120,000 ordinary shares — 6,000,000 options expiring on 1 July 2021 excisable at $0.25 Directorships held in listed entities — None William Garner — Non-Executive Chairman (appointed 1 July 2016) Qualifications — Master of Public Health, Harvard University Experience — Interest in Shares and Options — Doctor of Medicine, New York Medical College William Garner, MD is a US physician, investor, and entrepreneur. Dr Garner is one of the inventors on the Bisantrene patents, originally filed by Update Pharma, Inc. and now owned by Race Oncology. Previously, he founded EGB Advisors LLC, a life sciences advisory firm whose clients have included the M.D. Anderson Cancer Center, the Kauffman Foundation, ChemGenex (ASX:CXS) and CoTherix. He also founded Inverseon, Inc., which was merged with the ASX-listed company cBio to create Invion Ltd, serving as CEO until May of 2013. He founded Urigen Pharmaceuticals, Inc. and co-founded DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI). Previously, he was at Hoffmann La Roche in oncology medical affairs and worked as a merchant banker in New York City. Dr Garner currently serves as Chairman of InMed Pharmaceuticals (TSX:IN) & Isla Pharmaceuticals and works with several of the other portfolio companies of EGB Ventures. Dr Garner has a Master of Public Health from Harvard and received his MD degree from New York Medical College. Dr. Garner did residency training in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York. 15,200,000 ordinary shares 10,000,000 performance shares Directorships held in listed entities — Chairman of listed company InMed Pharmaceuticals (TSX:IN) 2 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT Chris Ntoumenopoulos — Non-Executive Director (appointed 27 April 2016) Qualifications — Bachelor of Commerce, majoring in Money and Banking, Investment Finance and Electronic Commerce Experience — Mr Ntoumenopoulos is Managing Director at Twenty 1 Corporate, a boutique corporate advisory firm. He has worked in financial markets for the past 12 years, focusing on Capital Raisings, Portfolio Management and Corporate Advisory. Mr Ntoumenopoulos has advised and funded numerous ASX companies from early stage venture capital, through to IPO. He is also a director of various private and public companies which span across finance, technology and medical sectors. Interest in Shares and Options — 606,250 ordinary shares — 1,000,000 options expiring on 22 November 2019 exercisable at $0.49 and 1,000,000 expiring on 22 November 2019 exercisable at $0.65 — ResApp Health Limited — Ookami Limited (resigned November 2015) John Cullity — Non-Executive Director (appointed 6 April 2018) Qualifications — MBBS, MRCP, MSc(Econs), MBA Experience — John is Managing Director at BioSynergy Partners, a New York and Melbourne based Directorships held in listed entities advisory recently spun out of Torreya – the renowned life sciences investment bank. He additionally, services on the Boards of several life sciences companies including Ceramedix (seeded by Torreya) and Race Oncology listed on ASX. He resides in New York. At Torreya, John provided strategic advisory on Mergers & Acquisitions, Partnering and Financing to life-science companies worldwide. Prior to joining Torreya, he was a senior member of the Business Development team at Sanofi Pharmaceuticals, where he led buy side transactions in oncology and diabetes. Earlier in his career, John was Head of Strategic Pricing & Reimbursement at Sanofi, Director of Health Economics at ScheringPlough, and Consultant at A.T. Kearney. He has also worked at The World Bank and the World Health Organization. John graduated in Medicine and sub-specialised in haematology-oncology at QE II Medical Centre, Perth. He holds a Bachelor of Medicine, Bachelor of Surgery from The University of Western Australia; Membership of the Royal College of Physicians; Masters in Health Economics from London School of Economics & Political Science, and MBA from The Wharton School, University of Pennsylvania. Interest in Shares and Options — None Directorships held in listed entities — None Brendan de Kauwe Qualifications Non-Executive Director (resigned 4 April 2018) — Bachelor of Science and Bachelor of Dental Surgery, University of Western Australia Post Graduate Diploma in Applied Finance, majoring in Corporate Finance, and is currently completing his Masters in Applied Finance Experience — Dr de Kauwe’s extensive science and bio-medical background with more than 10 years’ experience in the health sector; coupled with his finance backing, gives him an integral understanding in the evaluation of projects over a diverse range of sectors. Dr de Kauwe’s is a Director of Otsana Capital, a corporate advisory firm, with vast experience in corporate restructuring and recapitalisations, mergers and acquisitions, IPO/RTO and capital markets. Interest in Shares and Options — 590,000 ordinary shares 3 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT Directorships held in listed entities — G Medical Innovations Holdings Limited (current) Ookami Limited (current) e-Sense Lab Limited (ceased 29 March 2018) Calidus Resources Limited (ceased 13 June 2017) XPED Limited (ceased 24 March 2016) Company Secretary Peter Webse — Company Secretary (appointed 5 May 2016) Qualifications — B.Bus, FGIA, FCIS, FCPA, MAICD. Experience — Mr Webse has over 26 years' company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services. Meeting of Directors During the financial year 9 meetings of Directors were held. Attendances by each Director during the year are stated in the following table. DIRECTORS’ MEETINGS Number eligible to attend Number Attended Peter Molloy 9 9 William Garner 9 9 Chris Ntoumenopoulos 9 9 John Cullity (appointed 6 April 2018) 3 3 Brendan de Kauwe (resigned 4 April 2018) 6 6 Principal Activities Race Oncology is an Australian speciality pharmaceutical company whose business model is to pursue and bring to market later stage assets, principally in the cancer field. The Company’s first important asset is a chemotherapy drug, called Bisantrene, which was the subject of more than 40 phase II clinical studies, before it was lost in a series of pharmaceutical mergers during the 1990s. Race Oncology is rediscovering Bisantrene. Race Oncology owns recent patent filings on Bisantrene and has secured Orphan Drug Designation in the US. The Company’s goal is to complete final development of Bisantrene and bring this valuable cancer drug to market, initially for the treatment of Acute Myeloid Leukaemia (AML). Operating Results The operating loss after income tax amounted to $6,306,446 (2017: $4,171,555 loss); net cash used in operating activities was $3,869,392 (2017: (2,466,143)). Dividends Paid or Recommended No dividends were paid or are payable for the financial year. Review of Operations Race Oncology’s (Race) plan is to bring Bisantrene to market by seeking FDA approval in the longer term while in the shorter term, making the drug available for sale under a Named Patient Program (NPP), with the primary indication being Acute 4 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT Myeloid Leukaemia (AML). This plan has not changed since the Company listed in July 2016 and Race made further progress towards these two outcomes during the year, while adding an important new value stream shortly after year-end. Named Patient Program NPP activities A key short-term value driver for the Company is the expected generation of revenues from Named Patient Programs (NPP) in various countries. The initial focus was on France, Italy, Turkey and Korea. The Company’s NPP plans have now extended to the UK and other countries. During the year, major activities and milestones in support of the NPP strategy included: Completion of an initial GMP manufactured batches of Bisantrene Professional market research with haematological oncologists and pharmacists Group and individual meetings with doctors to present the Bisantrene clinical value proposition Publication of case reports on the successful historical use of Bisantrene Agreement with Durbin PLC to provide NPP distribution and market access Appointment of Dr Samar Al-Behaisi in May 2018 as Chief Medical Officer to drive NPP adoption MHRA approval for supply of Bisantrene under NPP Despite these initiatives, as at 30 June 2018, the Company had yet to report its first order or prescription from a doctor for supply of Bisantrene under an NPP. However, Race remains confident that the above initiatives will lead to NPP adoption and revenues during the 2018/19 year. Manufacturing Success On 12 September 2017, the Company announced the production of the first batch of Bisantrene under GMP (Good Manufacturing Practice) by its US manufacturing partner, IriSys LLC. Two batches have been released and are immediately available for supply to doctors under an NPP. Market Research and Meetings During the year, the Company funded market research studies in France, Italy and UK, to assess the opportunity and positioning for Bisantrene. This research consistently affirmed that there was positive interest in the opportunity to use Bisantrene in AML. In October 2017 and March 2018, the Company also arranged group meetings with AML specialists (haematological oncologists) in Paris to discuss Bisantrene use with French doctors. In June 2018, the Company held a similar meeting in London for UK and Italian AML specialists. These meetings included several doctors who had participated in the original Bisantrene AML studies published 25-30 years ago and who spoke positively of their experience with Bisantrene. Like the market research, the meetings reinforced the unmet medical need in relapsed/refractory AML and the opportunity for a chemotherapy agent like Bisantrene, which has a track record of success in relapsed and refractory (r/r) AML and the benefit of little or no cardiotoxicity Bisantrene’s effectiveness in childhood AML On 5 June 2018, Race announced a French case report describing the long-term use of Bisantrene to treat childhood AML. The report described two girls in France who were successfully treated with Bisantrene in 1984 and 1991, respectively. Both of them are alive today. The report was also published as a poster (available on the Company’s website) at the International Conference on Leukaemia and Haematologic Oncology in Paris on 21 June 2018. The authors were Prof. Guy Leverger, a leading French haematologyoncologist from Paris, and Prof. Yves Bertrand, also a leading AML specialist from Lyon. Both were involved in the original Bisantrene AML studies during the 1980s and 1990s. Durbin Agreement On 11 April 2018, Race announced that it had executed a global distribution agreement with UK-based, Durbin PLC. Durbin distributes pharmaceutical and healthcare products to 180 countries worldwide. They have global expertise in managed access programs, such as named patient programs (NPP). Under the agreement, Durbin will handle all the warehousing, invoicing, customer service and distribution of Bisantrene for a number of countries around the world. The Race CEO described the agreement as an important strategic partnership for Race because of Durbin’s expertise in NPP management and execution worldwide. The Durbin agreement is expected to significantly expand Race’s NPP footprint for Bisantrene, potentially covering countries such as: UK, Ireland, Benelux, Nordics, Central & Eastern Europe, Australia, New Zealand, Israel, Middle East and South Africa. 5 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT MHRA Approval On 21 June 2018, Race announced that Durbin had obtained approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for importation and distribution of Bisantrene as an unlicensed medicine in the UK. The approval allows Durbin to import and supply Bisantrene in the UK under a NPP. The initial approval is for 75 courses of treatment (14 vials per course), but Durbin can apply for additional approvals as needed. The MHRA approval also allows Durbin to supply Bisantrene for NPP outside the UK to all 28 other countries in the EEA (European Economic Area), subject to local approval and importation rules in each country. For example, in France, an ATU (French acronym for Temporary Authorisation for Use) is required in order to import and supply an unlicensed medicine. Clinical and FDA Approval Pathway Patents granted in US The Company considers US market approval to be the most important value driver for Bisantrene in the long-term. The Company currently has a seven-year post FDA approval market exclusivity in the under its US Orphan Drug Designation. In addition, the Company has been prosecuting two Bisantrene patent applications that would extend the FDA-mandated market exclusivity under the Orphan Drug Designation. On 29 January, Race advised the Notice of Allowance in US for one of the two Bisantrene patents. Subsequently, on 12 February, Race announced allowance of the second Bisantrene patent in the US. Subsequently, both patents have proceeded to grant in the US. The grant of these patents is considered an important event in that it extends the commercial protection in the US well beyond the Orphan Drug period and out to 2034. NCI Collaboration On 4 July 2017, the Company secured an agreement with National Cancer Institute (NCI) in the United States. Under the agreement, the Company was granted the right to use all the NCI data on Bisantrene and associated regulatory filings in support of the Bisantrene IND (Investigational New Drug Application) and obtaining regulatory approval for Bisantrene. Bisantrene Qualifies for 505(b)(2) During January 2018, the Company received formal advice from the FDA that Bisantrene qualifies for the expedited 505(b)(2) approval pathway, which allows Race to use all available historical preclinical and clinical data on Bisantrene in support of its New Drug Application (NDA). This includes the NCI data. Appointment of Chief Medical Officer On 15 May 2018, Race announced the appointment of Samar Al-Behaisi MD PhD, as Chief Medical Officer and Vice President of Medical Affairs for Race Oncology. Based in Switzerland - Dr Al-Behaisi will be responsible for oversight and direction of the Company’s clinical trials, while also driving the Named Patient Program (NPP). Since her appointment, Dr Al-Behaisi has been a driving force in building the Company’s presence with AML clinicians across Europe. CRO Appointed On 15 May 2018, Race announced that it had signed an agreement with Novotech, an Australian-based CRO (contract clinical research organisation) to manage the Bisantrene clinical trial program globally. The Company expects the trial will qualify for the R&D Tax Incentive scheme in Australia. Next Steps on Clinical Program The next steps in the clinical trial program are expected to include: Manufacturing of clinical trial stock for the trial Finalising the clinical protocol based on investigator feedback Filing the IND (Investigational New Drug) application FDA acceptance of the protocol, likely including a Special Protocol Assessment (SPA) to ensure the trial will support regulatory approval of Bisantrene Site initiation and other CRO activities to prepare to start the trial Because these activities involve a substantial cost commitment to Race during 2018/19, the next steps and timing of specific activities during 2018/19 are currently under review by the Race Board. 6 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT Other developments TargImmune Collaboration On 10 July 2017, the Company executed a letter of intent with TargImmune Therapeutics AG (Basel, Switzerland) to enter into a joint venture, focussed on developing cancer therapies based on combining Bisantrene with TargImmune’s targeted immunetherapy technology, CTPIC. The parties met several times during the year to discuss the project. Because of the apparent costs and complexities associated with a JV company based in Switzerland, it was determined that a less complex research collaboration should take place between the parties, having the same research goals as the JV. Under the proposed collaboration, Race and TargImmune would jointly fund the research. Discussions between the parties are expected to continue during 2018/19. New director On 4 April 2018, Race announced the appointment of Dr John Cullity as a non-executive director, effective 6 April 2018. Dr Cullity replaced Dr Brendan De Kauwe. Race is grateful for Brendan’s outstanding service as a director of Race Oncology Board since the founding of the Company. Dr Cullity’s appointment was an important one for Race, because he brings a wealth of medical oncology and business expertise to the Race board. Trained as a haematological oncologist, Dr Cullity previously held senior executive roles with Sanofi-Aventis and Schering-Plough in the US. Between 2010 and 2017 in New York, Dr Cullity was a principal for Torreya Partners, the internationally-recognised transactions firm, and established Torreya Insights, focusing on transactions advisory. During this time, he managed numerous licensing / M&A transactions and participated in the establishment of several biotech companies. With his deep understanding of the oncology business and his corporate transactional expertise, Dr Cullity is expected to be an important asset on the Race Board. RPD designation/PRV Immediately after the end of the year (16 July), Race announced that the FDA had granted Bisantrene a Rare Paediatric Disease (RPD) designation for treatment of childhood AML. This designation means Bisantrene has the opportunity to be awarded a Priority Review Voucher (PRV) at the time of marketing approval for childhood AML. If awarded, the PRV can be sold to other companies for a substantial value. The value of the PRV is entirely additive to the value of the NPP and the current FDA approval program (aimed at adult AML). As such, it adds a third important value domain for the Company, in addition to NPP revenues and the US FDA approval pathway. Over the coming year, Race expects to announce its plans to move forward the clinical program to support the designation and move towards a PRV. Funding The Company raised $6.1m in new funding during the year to support its operations: On 20 July 2017, the Company successfully completed a placement of 12.5 million ordinary shares at an issue price of $0.20, raising $2.5 million (in two tranches). This was followed on 12 March 2018 with an over-subscribed placement of 9.872 million shares at an issue price of $0.32, raising $3.169 million; oversubscriptions of 1.50 million shares were also accepted, bringing the total fundraising to $3.639 million. Following the March share placement, the Company agreed to issue 5,000,000 unlisted options at $0.45 and with a 24month expiry, to parties that assisted with the fundraising. The funds raised in March 2018 were intended to help expand the NPP program to new markets and manufacture new Bisantrene finished product to support a pivotal registration study towards FDA approval of Bisantrene. At 30 June 2018, the Company had cash reserves of approx. $3.7m. Significant Changes in State of Affairs During the year end the following significant changes in affairs occurred in addition to events mentioned above in the review of operations: On 22 November 2017, 4,000,000 unlisted options were issued to two Non-Executive Directors of the Company, expiring 22 November 2019. On 4 June 2018 2,000,000 options expired following the resignation of one of the Non-Executive Directors. The below exercise of unlisted options occurred during the year end: On 11 January 2018, 282,500 shares were issued following the exercise of $0.30 unlisted expiring 30 September 2018; On 9 February 2018, 56,250 shares were issued following the exercise of $0.30 unlisted expiring 30 September 2018; On 27 February 2018, 137,500 shares were issued following the exercise of $0.30 unlisted expiring 30 September 2018; On 13 April 2018, 50,000 shares were issued following the exercise of $0.30 unlisted expiring 30 September 2018; 7 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT On 16 May 2018, the Company granted 1,500,000 share options to the Company’s Chief Medical Officer, Dr Samar Al-Behaisi, exercisable at $0.32 and expiring 90 days after Termination of the Agreement or otherwise on the fifth anniversary of date of grant. The Company assessed that the milestones of the performance shares at balance date had been met within the vesting period. The satisfaction of the milestones resulted in the full value of $2,000,000 attributed to the performance shares being realised, which has been capitalised as an intangible asset, with the additional $500,000 capitalised during the year ended 30 June 2018, increasing the existing $1,500,000 value capitalised from the performance shares Financial Position The net assets of the Company at 30 June 2018 were $7,930,697 (2017: $5,637,289). Significant Events after the Reporting date On 2 July 2018 the Company announced the following transactions: the milestones for the two tranches of performance shares, each representing 5 million shares, have been met and are to be converted into fully paid ordinary shares at the election of holder, Update Pharma Inc. 10,000,00 unlisted $0.25 options were not exercised and expired on 1 July 2018. the Company issued 1,500,00 fully paid shares at an issue price of $0.32 pursuant to the terms of a placement announced to the market on the 12 March 2018 (Tranche 2 placement). the Company issued 5,000,000 unlisted $0.45 options exercised on or before 19 March 2020 issued pursuant to an advisory mandate. On 13 July 2018 the Company advised the following transactions: the Company issued 6,000,000 unlisted $0.30 options exercised on or before 13 January 2020 issued for the provision of corporate advisory services. the Company issued 1,500,000 unlisted $0.32 options exercised on or before 16 May 2023, issued pursuant to employee share option plan. On 18 July 2018, the Company announced that FDA had granted a Rare Paediatric Disease designation to Bisantrene in childhood AML, with the designation meaning that Bisantrene has the opportunity to be awarded a Priority Review Voucher from the FDA at time of approval. A Priority Review Voucher grants the holder an accelerated 6-month review of a drug application by the FDA. No matters or circumstances have arisen since the end of the financial year that significantly affect the operations of the Company, the results of those operations, or the state of the affairs of the Company in future financial years. Future Developments, Prospects and Business Strategies Race’s strategy continues to see the development of Bisantrene towards FDA approval, while making the drug available to patients under a Named Patient Program in certain countries. In addition, the RPD designation provides a new and additional value domain. Given the progress over the last 12 months, the management and board remain optimistic about the Company’s prospects in the 2018/19 year. Other than those matters noted elsewhere in this financial report, specific projections, developments and, future prospects and business strategies of operations have not been included, as the Directors believe, on reasonable grounds and based on the nature of the business, that the inclusion of such information would be likely to result in unreasonable prejudice to the Company. Environmental Regulations The Company aims to comply with the identified regulatory requirements in each jurisdiction in which it operates. There have been no known material breaches of the environmental regulations. Proceedings on Behalf of Company No person has applied for leave of Court to bring proceedings on behalf of the Company or intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those proceedings. The Company was not a party to any such proceedings during the year. 8 RACE ONCOLOGY LIMITED ACN 149 318 749 ANNUAL REPORT 30 JUNE 2018 DIRECTORS’ REPORT Share Options Unissued shares under option At the date of this report, the un-issued ordinary shares of Race Oncology Limited under option are as follows: Grant Date Expiry Date Exercise Price Number of shares under option 1 July 2016 1 July 2021 $0.25 9,000,000 22 November 2016 1 August 2021 $0.256 135,000 28 March 2017 1 April 2022 $0.25 1,500,000 8 May 2017 8 May 2022 $0.25 100,000 31 August 2017 30 September 2018 $0.30 9,723,750 22 November 2017 22 November 2019 $0.49 1,000,000 22 November 2017 22 November 2019 $0.65 1,000,000 20 June 2018